Novartis News

76,80 -0,67% -0,52 €
15.11.18 21:51:58 Uhr Tradegate | Mehr Kurse »
WKN: 904278
ISIN: CH0012005267
US-Symbol: NVSEF
Typ: Aktie

Ad-hocs

  
05.11.18 Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms GlobeNewswire
10.10.18 Novartis announces new data from the first direct head-​to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis GlobeNewswire
11.09.18 Alcon bestätigt vor dem vorgeschlagenen Spin-off von Novartis das Engagement in der Schweiz GlobeNewswire
11.09.18 Alcon confirms commitment to Switzerland ahead of proposed spinoff from Novartis GlobeNewswire
29.08.18 Alcon announces voluntary global market withdrawal of CyPass Micro-​Stent for surgical glaucoma GlobeNewswire
27.08.18 Novartis erhält die Zulassung für seine CAR-​T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen Kommission GlobeNewswire
27.08.18 Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) GlobeNewswire
25.08.18 Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode GlobeNewswire
23.07.18 Novartis renews drug donation of Egaten® (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke GlobeNewswire
19.07.18 Novartis demonstrates commitment to lead immuno-​dermatology by in-​licensing IL-17C compound for atopic dermatitis GlobeNewswire
16.05.18 Novartis kündigt Veränderungen in der Geschäftsleitung an GlobeNewswire
16.05.18 Novartis announces changes to the Executive Committee GlobeNewswire
18.04.18 Sandoz signs agreement with Pear Therapeutics to develop and commercialize prescription digital therapeutics for patients with substance use disorder and opioid use disorders GlobeNewswire
16.04.18 Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes GlobeNewswire
27.03.18 Novartis verkauft Beteiligung an Consumer-​Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren GlobeNewswire
27.03.18 Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities GlobeNewswire
12.03.18 Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an GlobeNewswire
12.03.18 Novartis announces changes to the Executive Committee to support strategic priorities GlobeNewswire
08.02.18 Novartis receives FDA approval for Cosentyx® label update to include moderate-​to-severe scalp psoriasis GlobeNewswire
24.01.18 Novartis erzielt 2017 eine gute operative Performance sowie wegweisende Innovationen und ist gut gerüstet für die nächste Wachstumsphase GlobeNewswire
24.01.18 Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase GlobeNewswire
16.01.18 Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA GlobeNewswire
15.12.17 Novartis gibt Rücktritt des Onkologie-​Chefs bekannt GlobeNewswire
15.12.17 Novartis announces Oncology head to retire GlobeNewswire
24.10.17 Novartis steigert im dritten Quartal Umsatz und Gewinn in allen Divisionen GlobeNewswire
24.10.17 Novartis delivered growth on top and bottom line in all divisions in Q3 GlobeNewswire
18.07.17 Die Ergebnisse im zweiten Quartal bestätigen die Jahresprognosen - starke Forschungs- und Entwicklungsresultate untermauern das Potenzial einiger hoch innovativer Produkte GlobeNewswire
18.07.17 Q2 results confirm full year guidance. Strong pipeline results underpin potential of several highly innovative products GlobeNewswire
20.06.17 Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval GlobeNewswire
20.06.17 Novartis real world study shows almost half of chronic urticaria patients are not receiving any treatment despite significant disease burden GlobeNewswire
31.05.17 At the Meet Novartis Management investor event, Novartis highlights focus on innovation and productivity; expects the next growth phase to begin in 2018 GlobeNewswire
04.05.17 Novartis exercises exclusive option agreement with Conatus for the treatment of NASH GlobeNewswire
25.04.17 Novartis erzielt Umsatzsteigerungen in allen Divisionen (kWk1), wobei Wachstumstreiber wie Cosentyx und Entresto die Einbussen durch Generika mehr als wettmachen; Innovationsdynamik setzt sich fort GlobeNewswire
25.04.17 Novartis delivered sales growth across all divisions (cc1) as growth drivers, including Cosentyx and Entresto, more than offset generic erosion; innovation momentum continued GlobeNewswire
23.03.17 Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction GlobeNewswire
22.03.17 Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure GlobeNewswire
13.03.17 Sandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk) GlobeNewswire
23.02.17 Novartis drug Zykadia receives FDA Priority Review for first-​line use in patients with ALK+ metastatic NSCLC GlobeNewswire
12.12.16 Novartis führt "SMS for Life 2.0" in Nigeria ein, um den Zugang zu unentbehrlichen Arzneimitteln zu verbessern GlobeNewswire
12.12.16 Novartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines GlobeNewswire
12.12.16 Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-​related macular degeneration (nAMD or wet AMD) GlobeNewswire
25.10.16 Novartis erzielt im dritten Quartal solide Ergebnisse, wobei die Wachstumsprodukte[1] den Verlust des Patents für Gleevec wettmachen; mehrere positive Daten für potenzielle Blockbuster GlobeNewswire
25.10.16 Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters GlobeNewswire
31.08.16 AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment GlobeNewswire
19.07.16 Novartis erzielt im 2. Quartal solide Ergebnisse trotz US-​Generikakonkurrenz für Gleevec im gesamten Quartal; wichtige positive Neuigkeiten zu Innovationen stärken zukünftige Wachstumsperspektiven GlobeNewswire
19.07.16 Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects GlobeNewswire
02.06.16 Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET) GlobeNewswire
25.05.16 Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event GlobeNewswire
21.04.16 Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums GlobeNewswire
21.04.16 Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth GlobeNewswire

Newssuche

  

Videos

  
15.11.18 +2,47%
DAX, Apple, WireCard: Das Korrektur-​Ende ist greifbar